Zolpidem impairs non-associative memory in mice;Zolpidem prejudica a memória não associativa em camundongos

Sleep Science

Volumn 4, Issue 3, 2011, Pages 81-87

  Zanin, Karina Agustini ^a   Patti, Camilla de Lima ^a   Tufik, Sérgio ^a   Poyares, Dalva ^a   Frussa Filho, Roberto ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypnotics and sedatives pharmacology; Locomotion; Memory drug effects; Memory physiology; Motor activity; Pyridines administration and dosage; Rats; Sleep

Indexed keywords

EID: 84876458416     PISSN: 19840659     EISSN: 19840063     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, et al. Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtype. Neurosci Biobehav Rev. 1994;18(3):335-72.
2. Depoortere HB, Zivkovic B, Lloyd KG, Sanger D, Perrault G, Langer SZ, et al. Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther. 1986;237(2):649-57.
3. Lloyd KG, Zivkovic B. Specificity within the GABA receptor supramolecular complex: a consideration of the new omega 1 receptor selective imidazopyridine hypnotic zolpidem. Pharmacol Biochem Behav. 1988;129(4):781-3.
4. Zivkovic B, Perrault G, Morel E, Sanger DJ. Comparative pharmacology of zolpidem and other hypnotics and sleep inducers. In: Sauvanet JP, Langer SZ, Morselli PL, editors. Imidazopyridines in sleep disorders: a novel experimental and therapeutic approach. New York: Raven Press; 1988. p. 97-109.
5. Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet. 1995;29(3):142-53.
6. Cashman JN, Power SJ, Jones RM. Assessment of a new hypnotic imidazo-pyridine (zolpidem) as oral premedication. Br J Clin Pharmac. 1987;24(1):85-92.
7. Langtry HD, Benfield P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs. 1990;40(2):291-313.
8. Evans SM, Funderburk FR, Griffiths RR. Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther. 1990;255(3):1246-55.
9. Diagnostic Classification Steering Committee of the American Sleep Disorders Association. International classification of sleep disorders-diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association; 1990.
10. Danjou P, Paty I, Fruncillo R, Worthington P, Unruh M, Cevallos W, et al. A comparison of the residual effects of zaleplon and zolpidem following administration 5 to 2 h before awakening. J Clin Pharmacol. 1999;48(3):367-74.
11. Dingemanse J, Bury M, Hussain Y, Van Giersbergen P. Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects. Drug Metab Dispos. 2000;28(12):1411-6.
12. Sanger DJ, Joly D, Zivkovic B. Effects of zolpidem, a new imidazopyridine hypnotic, on the acquisition of conditioned fear in mice. Comparison with triazolam and CL 218,872. Psychopharmacology (Berl). 1986;90(2):207-10.
13. Perrault G, Morel E, Sanger DJ, Zivkovic B. Differences in pharmacological profiles of a new generation of benzodiazepine and nonbenzodiazepine hypnotics. Eur J Pharmacol. 1990;187(3):487-94.
14. Sanger DJ, Morel E, Perrault G. Comparison of the pharmacological profiles of the hypnotic drugs zaleplon and zolpidem. Eur Pharmacol. 1996;313(1-2):35-42.
15. Siemiatkowski M, Sienkiewicz-Jarosz H, Członkowska AI, Bidziński A, Płaźnik A. Effects of buspirone, diazepam, and zolpidem on open field behavior, and brain [3H]muscimol binding after buspirone pretreatment. Pharmacol Biochem Behav. 2000;66(3):645-51.
16. Fahey JM, Grassi JM, Reddi JM, Greenblatt DJ. Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses. Pharmacol Biochem Behav. 2006;83(1):21-7.
17. González-Pardo H, Conejo NM, Arias JL. Oxidative metabolism of limbic structures after acute administration of diazepam, alprazolam and zolpidem. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1020-6.
18. Savić MM, Obradović DI, Ugresić ND, Cook JM, Yin W, Bokonjić DR. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and beta-CCt. Pharmacol Biochem Behav. 2004;79(2):279-90.
19. Cui XY, Zhao X, Chu QP, Chen BQ, Zhang YH. Influence of diltiazem on the behavior of zolpidem-treated mice in the elevated-plus maze test. J Neural Transm. 2007;114(2):155-60.
20. Kumar A, Goyal R. Possible GABAergic modulation in the protective effect of zolpidem in acute hypoxic stress-induced behavior alterations and oxidative damage. Neurochem Res. 2008;33(3):370-7.
21. Chodera A, Nowakowska E, Bartczak G. Tolerance to a new class of non-benzodiazepine anxiolytics. Pol J Pharmacol. 1994;46(5):479-81.
22. Tang AH, Smith MW, Carter DB, Im WB, Von Voigtlander PF. U-90042, a sedative/hypnotic compound that interacts differentially with the GABA-A receptor subtypes. J Pharmacol Exp Ther. 1995;275(2):761-
23. Edgar DM, Seidel WF, Gee KW, Lan NC, Field G, Xia H, et al. CCd-3693: an orally bioavailable analog of the endogenous neuroactive steroid, pregnanolone, demonstrates potent sedative hypnotic actions in the rat. J Pharmacol Exp. Ther. 1997;282(1):420-9.
24. Conceição IM, Maioline Júnior M, Mattia NF, Chang YH, Smaili S, Frussa-Filho R. Effect of withdrawal from long-term nifedipine administration on open-field habituation in the rat. Braz J Med Biol Res. 1994;27(6):1363-7.
25. Silva RH, Felicio LF, Nasello AG, Vital MA, Frussa-Filho R. Effect of ganglioside (GM1) on memory in senescent rats. Neurobiol Aging. 1996;17(4):583-6.
26. Vianna MR, Alonso M, Viola H, Quevedo J, de Paris F, Furman M, et al. Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat. Learn Mem. 2000;7(5):333-40.
27. Thiemann G, Fletcher BC, Ledent C, Molleman A, Hasenöhrl RU. The genetic versus pharmacological invalidation of the cannabinoid CB(1) receptor results in differential effects on 'non-associative' memory and forebrain monoamine concentrations in mice. Neurobiol Learn Mem. 2007;88(4):416-23.
28. Réus GZ, Valvassori SS, Machado RA, Martins MR, Gavioli EC, Quevedo J. Acute treatment with low doses of memantine does not impair aversive, non-associative and recognition memory in rats. Naunyn Schmiedebergs Arch Pharmacol. 2008;376(5):295-300.
29. Izquierdo I, Schröder N, Netto CA, Medina JH. Novelty causes time-dependent retrograde amnesia for one-trial avoidance in rats through NMDA receptor-and CaMKII-dependent mechanisms in the hippocampus. Eur J Neurosci. 1999;11(9):3323-8.
30. Patti CL, Frussa-Filho R, Silva RH, Carvalho RC, Kameda SR, Takatsu-Coleman AL, et al. Behavioral characterization of morphine effects on motor activity in mice. Pharmacol Biochem Behav. 2005;81(4):923-7.
31. Thenot JP, Hermann P, Durand A, Burke JT, Allen J, Garrigou D, et al. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL; editors. Imidazopyridines in sleep disorders. New York: Raven Press; 1988. p. 139-53.
32. Garrigou-Gadenne D, Burke JT, Durand A, Depoortere H, Thenot JP, Morseli PL. Pharmacokinetics, brain distribution and pharmaco-eletrocorticographic profile of zolpidem, a new hypnotic, in the rat. J Pharmacol Exp Therapeut. 1989;248(3):1283-8.
33. Puia G, Vicini S, Seeburg PH, Costa E. Influence of recombinant gamma-aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of gamma-aminobutyric acid-gated Cl-currents. Mol Pharmacol. 1991;39(6):691-6.
34. Sancar F, Ericksen SS, Kucken AM, Teissére JA, Czajkowski C. Structural determinants for high-affinity zolpidem binding to GABA-A receptors. Mol Pharmacol. 2007;71(1):38-46.
35. Crestani F, Martin JR, Möhler H, Rudolph U. Mechanism of action of the hypnotic zolpidem in vivo. Br J Pharmacol. 2000;131(7):1251-4.
36. Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav. 1998;61(3):253-69.
37. Cashman JN, Power SJ, Jones RM. Assessment of a new hypnotic imidazo-pyridine (zolpidem) as oral premedication. Br J Clin Pharmacol. 1987;24(1):85-9.
38. Herzog CD, Gandhi C, Bhattacharya P, Walsh TJ. Effects of intraseptal zolpidem and chlordiazapoxide on spatial working memory and high-affinity choline uptake in the hippocampus. Neurobiol Learn Mem. 2000;73(2):168-79.
39. Prut L, Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol. 2003;463(1-3):3-33.
40. Higashima M, Kinoshita H, Koshino Y. Differences in the effects of zolpidem and diazepam on recurrent inhibition and long-term potentiation in rat hippocampal slices. Neurosci Lett. 1998;245(2):77-80.
41. Rinaldi A, Mandillo S, Oliverio A, Mele A. D1 and D2 receptor antagonist injections in the prefrontal cortex selectively impair spatial learning in mice. Neuropsychopharmacol. 2007;32(2):309-19.
42. Izquierdo LA, Barros DM, Vianna MR, Coitinho A, de David e Silva T, Choi H, et al. Molecular pharmacological dissection of short-and long-term memory. Cell Mol Neurobiol. 2002;22(3):269-87.
43. Caceres LG, Aon Bertolino L, Saraceno GE, Zorrilla Zubilete MA, Uran SL, Capani F, et al. Hippocampal-related memory deficits and histological damage induced by neonatal ionizing radiation exposure. Role of oxidative status. Brain Res. 2010;1312:67-78.
44. Morgado I. [The psychobiology of learning and memory: fundamentals and recent advances]. Rev Neurol. 2005;40(5):289-97. Spanish.